ClinicalTrials.gg
RecruitingNCT05550402PARASMAUpdated Feb 20, 2024

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)

An interventional study of Salbutamol and Ipratropium Bromide in Asthma, Airway Obstruction and Airway Remodeling, sponsored by Hat Yai Medical Education Center. Recruiting at 1 site in Thailand. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Hat Yai Medical Education Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.

Planned enrollment
38th of 72
60 · median 63
Started
2024
with 8 others
No phase
17 of 72
3 open now
Registered
60th of 72
by date

Among the 72 studies testing albuterol in Asthma, this one is the 38th largest by planned enrollment, is one of 9 that started in 2024, is one of 17 with no phase, and was the 60th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About albuterol

Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies testing albuterol in Asthma, or all of them as a file.
02

Study summary

In asthma, the significant role of pathogenesis is chronic airway inflammation, bronchial hyperresponsiveness, and variable airflow obstruction. Asthma with irreversible or fixed airflow obstruction (FAO) is a clinical phenotype resulting from chronic airway inflammation with having longer disease duration, suggesting that airway remodeling contributes to the decline in lung function seen in individuals with asthma. Although this condition frequently occurs in patients with severe asthma, there are pieces of evidence occurring in those with mild to moderate asthma. According to previous research, low lung function, FEV1 less than 60% predicted, is a robust independent predictor of subsequent asthma attacks and other asthma outcomes, including asthma control and SABA use. In a recent study, the patients with mild to moderate asthma who received mild to medium dosed inhaled corticosteroid plus long-acting beta-2 agonist with or without asthma control showed evidence of FAO with or without bronchodilator reversibility. Therefore parasympathetic activity may be affected by FAO in those patients. The autonomic nervous system plays an essential role in asthma, especially from the parasympathetic, promoting bronchoconstriction and regulating airway inflammation and remodeling. This study hypothesizes that a cholinergic mechanism may play a significant role in FAO across patients with mild, moderate, and severe asthma. This might increase the fundamental evidence leading to early-step treatment with anti-cholinergic medication in early asthma severity driven by FAO.

03

Conditions studied

  • Asthma
  • Airway Obstruction
  • Airway Remodeling
  • Parasympathetic Nervous System Diseases

Keywords

  • asthma
  • fixed airway obstruction
  • spirometry
  • parasympathetic activity
  • well controlled
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthmatic patients classified by severity Mild (achieved control with using low-dose ICS or as-needed ICS-formoterol) or Moderate (achieved controlled with using low-dose ICS/LABA or Severe ((achieved controlled with using medium to high dose ICS/LABA)
  • Post-bronchodilator (Salbutamol) /FVC ratio less than 0.75 or below the Lower Limit of Normal (LLN) and Post-bronchodilator (Salbutamol) FEV1 predicted \< 80% with or without bronchodilator response
  • History of smoking less than 10 pack-years or current smoking
  • Patients who able to do spirometry without
  • asthma control was defined by ACQ6 \< 1.5

Exclusion criteria

Exclusion Criteria:

  • for spirometry
  • Chest x-ray suggested any chronic lung diseased
  • Contraindication for anticholinergic drug
  • History of asthma exacerbation within 12 weeks before visit 1
  • History of taking LAMA within 6 months before visit 1
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Salbutamol then ipratropium

    Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.

    Drug: Salbutamol · Drug: Ipratropium Bromide

  • Active comparator
    Ipratropium then salbutamol

    Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.

    Drug: Salbutamol · Drug: Ipratropium Bromide

  • Active comparator
    Salbutamol plus ipratropium

    Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium)

    Drug: Salbutamol plus Ipratropium Bromide

  • Placebo comparator
    Placebo

    Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).

    Other: Placebo

Interventions

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.

    Also known as: ventolin

  • DrugIpratropiumStudies of IpratropiumIpratropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.

    Also known as: Atrovent

  • DrugSalbutamol plus Ipratropium Bromide

    Drug pages: AlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IpratropiumStudies of IpratropiumIpratropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)

  • OtherPlacebo

    Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm).

06

What researchers measure

Primary outcomes

  1. Average FEV1

    FEV1 determined from serial spirometry and calculated on the basis of area under the curve

    Time frame: 6 hour

Secondary outcomes

  1. FEV1 at 6 h

    FEV1 at 6 hours post-dose

    Time frame: 6 hour

  2. Maximum FEV1

    Maximum FEV1 over the 6-hour serial assessments

    Time frame: 6 hour

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jun 2024, 3 months after the start.

Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 3 months is below that.

Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2022
First posted
Sep 22, 2022
StartActual
Feb 17, 2024
Primary completionEst.
Jun 1, 2024
CompletionEst.
Jun 30, 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05550402
Lead sponsor
Hat Yai Medical Education Center
Responsible party
Narongwit Nakwan (Asst. Prof., Hat Yai Medical Education Center) — Principal investigator
First posted
Sep 22, 2022
Start date
Feb 17, 2024
Primary completion
Jun 1, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Feb 20, 2024

Study contacts

Narongwit Nakwan, M.D.
Contact
naronak@hotmail.com
0818984566
Pattarawadee Taptawee, R.N.
Contact
taptawee@hotmail.co.th
Narongwit Nakwan, M.D.
principal investigator · Hatyai medical Education Center, Hatyai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Albuterol · Ipratropium

Start the discussion